FDA Floors Eli Lilly

Eli Lilly (NYSE: LLY  ) received an especially harsh rebuke from the FDA on Thursday about one of its top candidates. The agency refused to approve a long-lasting injection (LAI) version of the company's multibillion-dollar Zyprexa for schizophrenia and bipolar disorder.

In a surprise move, the Food and Drug Administration issued a non-approvable letter for the injection because of questions about the "excessive sedation events" seen in patients taking the drug. Rather than issue an approvable letter or a narrow label for the drug, the FDA ignored the advice of a somewhat positive advisory panel that had voted in favor of approval.  

The rejection of Zyprexa LAI is unfortunate for Lilly. It would have had a very strong competitive advantage versus other atypical antipsychotic drugs because of its superior every-four-week dosing. This long-acting treatment matters because schizophrenics often don't follow recommended dosing, and with it, it's relatively easy to see if a patient is sticking with his or her therapy.

There are already several long-lasting versions of the less desirable typical antipsychotics on the market. Johnson & Johnson's (NYSE: JNJ  ) and Alkermes' (Nasdaq: ALKS  ) Risperdal Consta, which had sales of $1.1 billion last year, is the only long-acting atypical antipsychotic drug on the market now, and its injections are effective for two weeks.

Other drugmakers, like Vanda Pharmaceuticals (Nasdaq: VNDA  ) , are also developing four-week-long injectable versions of atypical antipsychotic drugs, but Lilly's Zyprexa LAI was the only other long-acting atypical one with the opportunity to be approved soon.

Zyprexa LAI could have easily become a blockbuster therapy for Eli Lilly because of the huge need to improve many schizophrenics' compliance with therapy. The consolation prize for Lilly investors is that the FDA non-approvable letter won't affect sales of its Zyprexa tablets that are taken daily. But Zyprexa sales may come under pressure in the second half of the year as Johnson & Johnson's Risperdal starts to face generic competition.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 13, 2009, at 3:23 PM, withoutlimits wrote:

    Great! This company is very harmful. Do some research and it will be found that many a violent criminal is on this company's products.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 588821, ~/Articles/ArticleHandler.aspx, 9/18/2014 11:55:44 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement